NCT01511900已完成1 期
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAT-1004 in Patients With Type 2 Diabetes
Catabasis Pharmaceuticals0 个研究点目标入组 44 人开始时间: 2011年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
- 主要终点
- Frequency and severity of adverse events
研究概览
简要总结
The primary objective of the study is to evaluate the safety of escalating multiple doses over 2 weeks of CAT 1004 compared to placebo in patients with Type 2 diabetes (T2D).
Secondary objectives include evaluation of the pharmacokinetics (PK) and pharmacodynamics of escalating multiple doses of CAT-1004 in patients with T2D.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A patient must meet all of the following criteria to be in the study:
- •Age between 18 to 65 years inclusive at Screening.
- •Diagnosis of T2D:
- •For Part I:
- •Treated with any diet and exercise, with or without metformin (stable for ≥ 2 months).
- •HbA1c ≥ 7.0% and ≤ 10.0% if on diet and exercise alone, or ≥6.5 % and ≤ 9.0% if on metformin.
- •For Part II:
- •Stable on metformin for ≥ 2 months with HbA1c ≥ 7.0% and ≤ 10.0%.
- •Satisfies one of the following:
- •Females not of childbearing potential: non-pregnant and non-lactating; surgically sterile or postmenopausal for 2 years or at least 1 year with a follicle stimulating hormone assessment (FSH) greater than or equal to 40 IU/L; OR
- •Males: surgically sterile, abstinent, or patient or partner is utilizing an acceptable contraceptive method during and 3 months after the last study dose.
- •On a stable diet with body mass index (BMI): 25 to 40 kg/m2 inclusive at Screening with weight stable (± 4 kg) for > 6 weeks prior to Screening.
排除标准
- •A patient will not be eligible if any of the following criteria apply:
- •Use of prescription medications other than allowed medications within 30 days of planned admission to the clinic. Allowed medications include metformin, anti-hypertensives, lipid-lowering medications, thyroid replacement therapy, low-dose aspirin (81 mg/day), proton pump inhibitors and anti-depressants. Prescribed doses of these medications must have been stable for 2 months at the time of first dose.
- •Clinically significant abnormalities in physical examination or vital signs at screening
- •Clinically significant electrocardiogram (ECG) abnormalities as assessed by the investigator.
- •Clinically significant laboratory result as assessed by the Investigator.
- •The patient has a history of clinically significant medical disease including significant allergies (except for untreated, asymptomatic seasonal allergies at the time of dosing), or hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease, other than T2D, hypertension, dyslipidemia, hypothyroidism or depression.
- •History or presence of malignancy within the past 5 years.
- •History of Type 1 diabetes or clinically significant cardiovascular disease (including a history of unstable angina, acute myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention, or New York Heart Association Class III or IV congestive heart failure within 6 months prior to screening) or clinically significant renal disease.
- •History of alcohol or substance abuse or eating disorder within 2 years, OR regular use of alcohol within 6 months (>14 units of alcohol per week; 1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol).
- •Use of any investigational drug or participation in any investigational study within 30 days prior to screening or 5 half-lives of the study agent, whichever is longer.
研究组 & 干预措施
Cohort 1: Dose level 1
Experimental
Multiple dose orally: CAT-1004 Dose level 1 or placebo
干预措施: CAT 1004 (Drug)
Cohort 1: Dose level 1
Experimental
Multiple dose orally: CAT-1004 Dose level 1 or placebo
干预措施: Placebo (Drug)
Cohort 2: Dose level 2
Experimental
Multiple dose orally: CAT-1004 Dose level 2 or placebo
干预措施: Placebo (Drug)
Cohort 2: Dose level 2
Experimental
Multiple dose orally: CAT-1004 Dose level 2 or placebo
干预措施: CAT 1004 (Drug)
Cohort 3: Dose level 3
Experimental
Multiple dose orally: CAT-1004 Dose level 3 or placebo
干预措施: Placebo (Drug)
Cohort 3: Dose level 3
Experimental
Multiple dose orally: CAT-1004 Dose level 3 or placebo
干预措施: CAT 1004 (Drug)
Cohort 4: Dose level 4
Experimental
Multiple dose orally: CAT-1004 Dose level 4 or placebo
干预措施: Placebo (Drug)
Cohort 4: Dose level 4
Experimental
Multiple dose orally: CAT-1004 Dose level 4 or placebo
干预措施: CAT 1004 (Drug)
Cohort 5: Dose level TBD
Experimental
Multiple dose orally: CAT-1004 Dose level TBD or placebo
干预措施: Placebo (Drug)
Cohort 5: Dose level TBD
Experimental
Multiple dose orally: CAT-1004 Dose level TBD or placebo
干预措施: CAT 1004 (Drug)
结局指标
主要结局
Frequency and severity of adverse events
时间窗: Screening to Follow-up (Day 25)
次要结局
- Cmax of CAT-1004(Days 1, 7 and 14)
- Glucose area under the curve for 0-24 hrs/24 and 0-4 hrs/4(Day -2 through f/u (Day 25))
- Changes from baseline for hematology, chemistry, coagulation and urinalysis(Baseline through End of study (Day 25))
- Changes from baseline in vital signs(Baseline through end of study (Day 25))
- Changes from baseline for ECGs(Baseline through end of study (Day 25))
- AUCinf of CAT-1004(Days 1, 7 and 14)
- Changes from baseline for Physical exams(Baseline through end of study (Day 25))
研究者
相似试验
Unknown
1 期
A Study of TG103 in Subjects With Type 2 DiabetesType 2 DiabetesNCT04790006CSPC ZhongQi Pharmaceutical Technology Co., Ltd.54
已完成
1 期
Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy SubjectsHealthyNCT02162355Galapagos NV36
终止
1 期
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788HealthyNCT02255968Enanta Pharmaceuticals, Inc16
已完成
1 期
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult VolunteersHealthyNCT02228707Biogen56
已完成
1 期
VNRX-5024 Safety and PK in Healthy Adult VolunteersHealthy SubjectsNCT04314206Basilea Pharmaceutica36